Goldman Sachs is out with its report today on United Therapeutics UTHR, lowering its PT to $52 from $82.
In its report, Goldman Sachs writes, "We are reducing our 12-month price target to $52 from $82, as we now
exclude oral Remodulin from our estimates and valuation and we have also lowered our M&A ranking to '3' from '1.' Our 12-month price target $52 is derived from a 50%/50% blend of our SOTP ($54) and DCF ($50)
value."
Goldman Sachs maintains Buy on UTHR.
Shares of UTHR closed Wednesday at $39.91, down 18.15% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in